Overview

Synthetic version of naturally occurring thymosin beta-4. Promotes tissue regeneration, wound healing, and reduces inflammation.

Global Regulatory Status

Approval status across major regulatory agencies worldwide.

FDA
United States
Research
TGA
Australia
Not Approved
EMA
European Union
Not Approved
MHRA
United Kingdom
Not Approved
PMDA
Japan
Not Approved
NMPA
China
Not Approved
Note: "Unknown" status indicates that comprehensive regulatory information is not yet available in our database. This does not necessarily mean the peptide is not approved. For critical medical decisions, always verify current regulatory status with the relevant health authority.

Mechanism of Action

Promotes cell migration and differentiation, upregulates actin, stimulates angiogenesis, reduces inflammation via NF-κB pathway modulation.

Stability & Storage

Form Storage Conditions Shelf Life
Lyophilised
(Freeze-Dried)
Store lyophilized powder at -20°C for long-term storage (12-24 months). Can be stored at 2-8°C for up to 6 months. Protect from light. 12-24 months
Reconstituted
Solution
After reconstitution with bacteriostatic water, store at 2-8°C for up to 21-28 days. With sterile water, use within 5-7 days. Avoid freeze-thaw cycles. 21-28 days
⚠️ Storage Best Practices
  • Always store in original packaging until ready to use
  • Protect from light, moisture, and temperature fluctuations
  • Never refreeze after thawing
  • Use proper sterile technique when reconstituting
  • Discard if solution becomes cloudy or discolored

Target Information

Target Receptors
No specific receptor; acts through actin-binding and intracellular signaling modulation
Target Tissues
  • Connective tissue
  • muscle tissue
  • epithelial tissue
  • vascular endothelium
  • neural tissue
Target Organs
  • Heart
  • skeletal muscle
  • tendons
  • ligaments
  • skin
  • blood vessels
  • brain
  • gastrointestinal tract

Pharmacokinetics: Half-Life by Administration Route

The biological half-life varies significantly depending on the route of administration. This affects dosing frequency and duration of action.

Administration Route Half-Life Clinical Implications
Intravenous (IV) Approximately 2 hours when administered intravenously based on clinical pharmacokinetic studies Direct bloodstream entry, fastest onset, shortest duration
Subcutaneous (SC) Approximately 2.4 hours after subcutaneous injection in circulation, with tissue residence time sign Slower absorption, sustained release, most common route

Note: Half-life values can vary between individuals based on factors including age, metabolism, kidney/liver function, and co-administered medications.

Molecular Structure

Amino Acid Sequence

2D Chemical Structure

2D Structure Visualization Pending

This peptide contains 43 amino acids.

For larger peptides, the amino acid sequence (shown above) provides the most accurate representation of structure.

2D chemical structure visualization is most effective for peptides with <10 amino acids.

3D Molecular Model

3D structure model will be available soon

Structure visualization powered by 3Dmol.js (integration pending)

Peptide Composition & Modifications

Amino Acid Composition

Natural L-Amino Acids
43 residues
Total Length
43 amino acids

Terminus Modifications

N-Terminus (Amino Terminus)
Acetylated (N-acetyl-Serine)
C-Terminus (Carboxyl Terminus)
Free COOH (Serine)

Terminal modifications can protect against exopeptidase degradation and modulate biological activity.

Nomenclature

Standard Abbreviation
TB-500
Also Known As
  • Thymosin Beta-4
  • Tβ4
  • TB4
  • Thymosin β4

Dosage & Administration

Research doses: 2-10 mg weekly, SC

⚠️ Medical Supervision Required

This information is for educational purposes only. Dosing should only be determined by a qualified healthcare provider based on individual patient needs and medical history.

Scientific References

References are organized by topic for easy navigation. Click on PubMed links to view the full articles.

Clinical Trials

Morris DC, et al.
Efficacy and safety of intravenous thymosin β4 in acute stroke patients
Journal of Investigative Medicine (2014)

Mechanism of Action

Goldstein AL, et al.
Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications
Annals of the New York Academy of Sciences (2005)

Wound Healing

Philp D, et al.
Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development
Journal of Cell Science (2004)

Research & Clinical Status

FDA approved for veterinary use. Human trials ongoing.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or medication. The information provided here is based on available scientific literature and may not be complete or up-to-date.